Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • Orchestra BioMed Holdings' Other Accumulated Expenses rose 4387.76% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 4387.76%. This contributed to the annual value of $579000.0 for FY2024, which is 4633.92% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Other Accumulated Expenses stood at $1.7 million for Q3 2025, which was up 4387.76% from $879000.0 recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Other Accumulated Expenses peaked at $1.9 million during Q4 2022, and registered a low of $379000.0 during Q2 2024.
  • For the 4-year period, Orchestra BioMed Holdings' Other Accumulated Expenses averaged around $1.1 million, with its median value being $1.0 million (2023).
  • In the last 5 years, Orchestra BioMed Holdings' Other Accumulated Expenses plummeted by 6120.78% in 2024 and then surged by 13192.61% in 2025.
  • Orchestra BioMed Holdings' Other Accumulated Expenses (Quarter) stood at $1.9 million in 2022, then tumbled by 43.0% to $1.1 million in 2023, then crashed by 46.34% to $579000.0 in 2024, then surged by 192.23% to $1.7 million in 2025.
  • Its Other Accumulated Expenses stands at $1.7 million for Q3 2025, versus $879000.0 for Q2 2025 and $1.1 million for Q1 2025.